-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AT-193 in Plaque Psoriasis (Psoriasis Vulgaris)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AT-193 in Plaque Psoriasis (Psoriasis Vulgaris) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AT-193 in Plaque Psoriasis (Psoriasis Vulgaris) Drug Details: AT-193 is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AT-193 in Hidradenitis Suppurativa
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AT-193 in Hidradenitis Suppurativa report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AT-193 in Hidradenitis Suppurativa Drug Details: AT-193 is under development for the...
-
Product Insights
Hidradenitis Suppurativa – Drugs In Development, 2023
Global Markets Direct’s, ‘Hidradenitis Suppurativa - Drugs In Development, 2023’, provides an overview of the Hidradenitis Suppurativa pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hidradenitis Suppurativa, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Psoriatic Arthritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Psoriatic Arthritis - Drugs In Development, 2023’, provides an overview of the Psoriatic Arthritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Psoriatic Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Plaque Psoriasis (Psoriasis Vulgaris) – Drugs In Development, 2023
Global Markets Direct’s, ‘Plaque Psoriasis (Psoriasis Vulgaris) - Drugs In Development, 2023’, provides an overview of the Plaque Psoriasis (Psoriasis Vulgaris) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Aberdeen Standard Invts/ Azora / CBRE Global Inv – River Park Residential Complex – Madrid
Equip yourself with the essential tools needed to make informed and profitable decisions with our Aberdeen Standard Invts/ Azora / CBRE Global Inv - River Park Residential Complex - Madrid report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AT-193
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry AT-193 Drug Details AT-193 is under development for the treatment of hidradenitis suppurativa and...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AT-177
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry AT-177 Drug Details AT-177 is under development for the treatment of ulcerative colitis. It...
-
Product Insights
Psoriatic Arthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Psoriatic arthritis is a form of arthritis that affects some people who have psoriasis. Symptoms include swollen fingers and toes, foot pain, and lower back pain. Risk factors include age, family history, and psoriasis. Treatment includes NSAIDs, immunosuppressants, and surgery. The Psoriatic Arthritis pipeline drugs market research report provides comprehensive information on the therapeutics under development for Psoriatic Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The...
-
Product Insights
Ulcerative Colitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ulcerative Colitis – Drugs In Development, 2022, provides an overview of the Ulcerative Colitis (Gastrointestinal) pipeline landscape. Ulcerative Colitis (Colitis ulcerosa or UC) is a chronic disease mainly of the large intestine or colon and a type of Inflammatory Bowel Disease (IBD). The disease is characterized by open sores and ulcers in the colon. The risk factors for UC include smoking, family history of the disease, liver disease, colon cancer,...